| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 109, 1122-1126, Copyright © 1981 by Endocrine Society
ARTICLES |
PM Conn, DC Rogers and T Sheffield
In the present work, we show that pimozide is a noncompetitive antagonist of gonadotropin-releasing hormone (GnRH)-stimulated LH release from pituitary cell cultures. For several other neurotropic agents, the concentration needed to inhibit 50% of LH release in response to GnRH correlates well with the ability to inhibit enzyme activation by calmodulin in vitro. Pimozide does not alter the affinity or amount of releasing hormone binding by the GnRH receptor. The additional observation that pimozide inhibits Ca2+ ionophore (A23187 and ionomycin)-stimulated LH release suggests that the locus of pimozide action is after Ca2+ mobilization. Pimozide is known to bind and inactivate the Ca2+-calmodulin complex, and as Ca2+ is a second messenger for GnRH, it is possible that calmodulin is the target of pimozide in this system.
This article has been cited by other articles:
![]() |
M. C. H. Holland, S. Hassin, and Y. Zohar Effects of Long-Term Testosterone, Gonadotropin-Releasing Hormone Agonist, and Pimozide Treatments on Gonadotropin II Levels and Ovarian Development in Juvenile Female Striped Bass (Morone saxatilis) Biol Reprod, November 1, 1998; 59(5): 1153 - 1162. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |